[Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future]
- PMID: 28394532
- DOI: 10.18565/urol.2017.1.103-107
[Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future]
Abstract
This review article describes the differences in efficacy and side effects between available phosphodiesterase type 5 (PDE-5) inhibitors used for treating erectile dysfunction. The most studied PDE-5 inhibitor is sildenafil.
Keywords: erectile dysfunction; phosphodiesterase type 5 inhibitors; safety; sildenafil; tadalafil; vardenafil.
Similar articles
-
Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.J Sex Med. 2020 May;17(5):941-948. doi: 10.1016/j.jsxm.2020.01.027. Epub 2020 Mar 3. J Sex Med. 2020. PMID: 32144034 Free PMC article.
-
Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.Int J Clin Pract. 2015 Apr;69(4):436-43. doi: 10.1111/ijcp.12548. Epub 2014 Oct 14. Int J Clin Pract. 2015. PMID: 25311239
-
PDE-5 inhibitors: clinical points.Curr Drug Targets. 2015;16(5):420-6. doi: 10.2174/1389450115666141111111301. Curr Drug Targets. 2015. PMID: 25392015 Review.
-
Lodenafil.Profiles Drug Subst Excip Relat Methodol. 2022;47:113-147. doi: 10.1016/bs.podrm.2021.10.004. Epub 2021 Dec 7. Profiles Drug Subst Excip Relat Methodol. 2022. PMID: 35396013 Review.
-
[Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].Urologiia. 2021 May;(2):135-140. Urologiia. 2021. PMID: 33960173 Russian.
Cited by
-
Increased serum asprosin is correlated with diabetes mellitus-induced erectile dysfunction.Diabetol Metab Syndr. 2024 Apr 24;16(1):91. doi: 10.1186/s13098-024-01333-9. Diabetol Metab Syndr. 2024. PMID: 38659035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous